Inotek Pharmaceuticals Corp (ITEK) Files Form 4 Insider Buying : J Martin Carroll Buys 10,000 Shares

Inotek Pharmaceuticals Corp (ITEK): J Martin Carroll , director of Inotek Pharmaceuticals Corp purchased 10,000 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $9.03 per share for a total value of $90,294.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 25, 2015, Argeris N Karabelas (director 10% owner) purchased 603,832 shares at $6.00 per share price.On Feb 25, 2015, Devang Kantesaria (10% owner) purchased 814,166 shares at $6.00 per share price.Also, On Feb 25, 2015, Ventures, Inc. Medimmune (10% owner) purchased 416,667 shares at $6.00 per share price.

Inotek Pharmaceuticals Corp: On Monday, May 16, 2016 heightened volatility was witnessed in Inotek Pharmaceuticals Corp which led to swings in the share price. The shares opened for trading at $9 and hit $9.17 on the upside , eventually ending the session at $9.06, with a gain of 0.22% or 0.02 points. The heightened volatility saw the trading volume jump to 1,11,480 shares. The 52-week high of the share price is $19.45 and the company has a market cap of $239 M . The 52-week low of the share price is at $4.71.

Inotek Pharmaceuticals Corp Money Flow Index Chart

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Company’s business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery development and commercialization of therapies for glaucoma. Its lead product candidate trabodenoson is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company’s product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).

Leave a Reply

Inotek Pharmaceuticals Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Inotek Pharmaceuticals Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.